Correction: *CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy*

Xiao M, Xie L, Cao G, *et al*. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. *J Immunother Cancer* 2022;10:e004022. doi: 10.1136/jitc-2021-004022

The funding statement has been updated to:

This study was supported by grants from the National Key Research and Development Program of China (NO. 2021YFC-2300602 to LY) and the National Natural Science Foundation of China (No. 32030041 to LY, No. 81702443 to SL).

J Immunother Cancer 2022;**10**:e004022corr1. doi:10.1136/jitc-2021-004022corr1